Janux Net Profit Margin from 2010 to 2025

JANX Stock  USD 32.89  0.88  2.75%   
Janux Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to -6.84 in 2025. Net Loss is the percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(6.52)
Current Value
(6.84)
Quarterly Volatility
1.01690097
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Janux Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Janux Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 15.1 M, Depreciation And Amortization of 2.4 M or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 285, Dividend Yield of 0.0 or PTB Ratio of 2.95. Janux financial statements analysis is a perfect complement when working with Janux Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Janux Therapeutics Correlation against competitors.
For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

Latest Janux Therapeutics' Net Profit Margin Growth Pattern

Below is the plot of the Net Profit Margin of Janux Therapeutics over the last few years. It is the percentage of revenue left after all expenses have been deducted from sales. The measure is calculated by dividing net profit by revenue. Janux Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Janux Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Profit Margin10 Years Trend
Slightly volatile
   Net Profit Margin   
       Timeline  

Janux Net Profit Margin Regression Statistics

Arithmetic Mean(8.39)
Geometric Mean8.33
Coefficient Of Variation(12.12)
Mean Deviation0.84
Median(8.95)
Standard Deviation1.02
Sample Variance1.03
Range2.664
R-Value0.73
Mean Square Error0.51
R-Squared0.54
Significance0
Slope0.16
Total Sum of Squares15.51

Janux Net Profit Margin History

2025 -6.84
2024 -6.52
2023 -7.21
2022 -6.29

About Janux Therapeutics Financial Statements

Janux Therapeutics investors use historical fundamental indicators, such as Janux Therapeutics' Net Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Janux Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss(6.52)(6.84)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.